<DOC>
	<DOCNO>NCT02665312</DOCNO>
	<brief_summary>observational prospective study , design patient colorectal cancer receive first time 5-FU capecitabine , without chemotherapy combination .</brief_summary>
	<brief_title>Cardiotoxicity Risk Factors Patients With Colorectal Cancer Receiving Fluoropyrimidine</brief_title>
	<detailed_description>All patient enrol evaluated cardiovascular risk factor , result cardiovascular risk , submit cardiac examination therapy optimization start chemotherapy . Patients evaluate 12-lead ECG blood sample TnI NT pro-BNP start chemotherapy day 3 chemotherapy first , second third cycle . All patient develop cardiovascular event submit blood sample TnI , NT-proBNP , hsTnI cardiac examination .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Signed write informed consent Age â‰¥ 18 year Histologically confirm adenocarcinoma colon rectum ( T , N , M ) receive first time 5FU capecitabine , without chemotherapy combination Prior treatment fluoropyrimidines Prior concurrent chest radiotherapy Any prior concurrent treatment cardiotoxic drug Any serious uncontrolled cardiovascular disease ( defined specialist cardiac examination , see section 6.3.2 detail )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cardiotoxicity</keyword>
	<keyword>fluoropyrimidine</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>